本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次调整原因：南京伟思医疗科技股份有限公司（以下简称"公司"）自 2023 年度利润分配及资本公积金转增股本预案披露之日起至本公告披露日，公 司通过上海证券交易所交易系统以集中竞价交易方式新增回购公司股份 115,973 股。截至本公告披露日，公司回购专用证券账户中股份数量为 755,314 股。根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，上市公司回购专用证券账户中的股份不享有利润分配、公积金转增股本的 权利。目前公司总股本为 68,623,867 股，因此公司实际参与分配的股本总数为 67,868,553 股。按照现金分红分配总额不变、每股转增比例不变的原则，对公司 2023 年度利润分配及资本公积金转增股本预案中的每股现金分红金额、资本公 积转增股本总额进行相应调整。 一、经审议通过的 2023 年度利润分配及资本公积转增股本方案 公司于 2024 年 4 月 25 日召开第三届董事会第十七次会议、第三届监事会第 十五次会 ...

重要内容提示： 证券代码：688580 证券简称：伟思医疗 公告编号：2024-023 说明会暨 2024 年第一季度业绩说明会的公告 南京伟思医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 关于参加 2023 年度科创板医疗设备专场集体业绩 会议线上交流时间：2024 年 5 月 24 日(星期五) 下午 15:00-17:00 会议召开方式：线上文字互动 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 投资者可于 2024 年 5 月 23 日(星期四)下午 16:00 前通过邮件、电话等形式将 需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关 注的问题进行回答。 南京伟思医疗科技股份有限公司（以下简称"公司"）已于 2024 年 4 月 26 日披露《2023 年年度报告》及《2024 年第一季度报告》，为便于广大投资者更 全面深入地了解公司 2023 年度 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [2] Core Views - Despite short-term pressure on business due to factors like a slowdown in bidding in Q1 2024, the company's core business continues to show comprehensive growth, and new businesses are expected to contribute additional growth in the second half of the year [7] - The company achieved a revenue of 462.22 million yuan in 2023, representing a year-on-year growth of 43.72%, and a net profit attributable to shareholders of 136.26 million yuan, up 45.22% year-on-year [1][8] Performance Summary - In 2023, the company reported operating revenue of 462.22 million yuan, a year-on-year increase of 43.72% - The net profit attributable to shareholders reached 136.26 million yuan, growing by 45.22% year-on-year - The first quarter of 2023 saw a revenue of 88 million yuan, a decrease of 8.24% year-on-year, and a net profit of 22 million yuan, down 27.69% year-on-year, primarily due to external factors like a slowdown in bidding [1] Product Performance - The revenue from magnetic stimulation products was 199.55 million yuan, up 46.59% year-on-year - Revenue from electrical stimulation products was 62.94 million yuan, growing by 6.8% - Electrophysiological products generated 64.78 million yuan, a 30.67% increase - Consumables and accessories revenue reached 76.18 million yuan, up 30.68% - Laser radiofrequency products saw a significant increase in revenue to 37.33 million yuan, up 476.5% [1] Research and Development - The company invested 58 million yuan in R&D in 2023, an increase of 31.83% year-on-year, with an R&D expense ratio of 12.47%, a decrease of 1.12 percentage points - The company applied for 36 new patents, including 16 invention patents, and received 47 new patent grants [1] Financial Metrics - The company's management expense ratio was 10.27%, down 1.59 percentage points year-on-year - The sales expense ratio was 26.75%, down 1.71 percentage points year-on-year - The sales gross margin was 71.76%, a decrease of 0.71 percentage points year-on-year, while the net profit margin was 29.48%, an increase of 0.31 percentage points year-on-year [1]

南京伟思医疗科技股份有限公司 2023 年年度股东大会会议资料 证券代码：688580 证券简称：伟思医疗 南京伟思医疗科技股份有限公司 2023年年度股东大会会议资料 2024 年 5 月 南京伟思医疗科技股份有限公司 2023 年年度股东大会会议资料 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等权 利。股东及股东代理人参加股东大会应认真履行其法定义务，不得侵犯公司和其 他股东及股东代理人的合法权益，不得扰乱股东大会的正常秩序。 五、股东及股东代理人要求在股东大会现场会议上发言的，应于股东大会召 开前一天向大会会务组进行登记。大会主持人根据会务组提供的名单和顺序安排 发言。 2023 年年度股东大会会议资料目录 | 2023 | | 年年度股东大会会议须知 1 | | | --- | --- | --- | --- | | 2023 | | 年年度股东大会会议议程 3 | | | 议案 | 1：关于公司《2023 | 年度董事会工作报告》的议案 5 | | | 议案 | 2：关于公司《2023 | 年度监事会工作报告》的议案 6 | | | ...

伟思医疗（ [Table_StockNameRptType] 688580） 公司研究/公司点评 敬请参阅末页重要声明及评级说明 证券研究报告 计医美板块也将为公司贡献 3000 万元左右收入，未来随着医美设备增 多，公司医美板块的业绩会呈现更快速增长。 ⚫ 风险提示 | --- | --- | --- | --- | --- | |-------------------|-------|-------------------------|-------|-------| | 主要财务指标 | 2023A | 2024E | 2025E | 2026E | | 营业收入 | | 462 589 741 933 | | | | 收入同比（ % ） | 43.7% | 27.4% | 25.9% | 25.9% | | 归属母公司净利润 | | 136 170 215 272 | | | | 净利润同比（ % ） | 45.2% | 25.0% | 26.2% | 26.5% | | 毛利率（ % ） | 71.8% | 72.1% | 72.5% | 72.8% | | ROE （ % ） | 8.4% | 9 ...

关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/11/10 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 2,000 万元~4,000 万元 | | 回购用途 | 用于股权激励、用于转换公司可转债 | | 累计已回购股数 | 35.3866 万股 | | 累计已回购股数占总股本比例 | 0.5157% | | 累计已回购金额 | 1,810.69854 万元 | | 实际回购价格区间 | 41.23 元/股~65.88 元/股 | 证券代码：688580 证券简称：伟思医疗 公告编号：2024-020 南京伟思医疗科技股份有限公司 2023 年 11 月 9 日，南京伟思医疗科技股份有限公司（以下简称"公司"）召 开第三届董事会第十六次会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，同意公司通过集中竞价交易方式回购公司已发行的人民币普通 股 ...

Investment Rating - The report gives a "Cautious Recommend" rating to the company, with an expected PE ratio of 20/16/13 for 2024-2026 [60] Core Views - The company's traditional core business maintains stable growth, while new businesses gradually contribute to performance increments [60] - The company is transitioning from traditional businesses to high-end sectors such as laser and medical aesthetics [60] - The company's R&D investment in 2023 was 78.43 million yuan, accounting for 16.97% of revenue, with a year-on-year increase of 27.86% [24] Industry Overview - The number of rehabilitation medical institutions in China increased from 396 in 2014 to 810 in 2021, with an average annual increase of about 60 institutions [3] - The number of practitioners in rehabilitation medical institutions grew from 31,445 in 2014 to 87,507 in 2021, with a CAGR of 15.74% [3] - The number of outpatient and emergency visits in rehabilitation departments grew at a CAGR of 5.60% from 2014 to 2021, significantly higher than the overall growth rate of outpatient visits [3] Company Business Segments - The company's core business areas include pelvic floor and postpartum rehabilitation, mental rehabilitation, and neurological rehabilitation [4] - In the pelvic floor field, the company launched its second-generation pelvic floor magnetic stimulation product in 2023, integrating biofeedback with passive stimulation [4] - In the mental rehabilitation field, the company launched its second-generation transcranial magnetic stimulation device in 2023, significantly improving treatment effects [4] - In the neurological rehabilitation field, the company provides advanced non-invasive neuromodulation treatment methods and offers a comprehensive "Rehabilitation Loop" solution for tertiary hospitals [4] Financial Performance - In 2023, the company achieved revenue of 462.22 million yuan, a year-on-year increase of 43.72%, and net profit attributable to the parent company of 136.26 million yuan, a year-on-year increase of 45.22% [64] - In Q1 2024, the company's revenue was 88 million yuan, a year-on-year decrease of 8.24%, and net profit attributable to the parent company was 22 million yuan, a year-on-year decrease of 27.69% [15] - The company's gross profit margin in 2023 was 71.76%, with a slight decline of 0.71 percentage points year-on-year [60] R&D and Innovation - The company has established six technology platforms: magnetic stimulation, electrical stimulation, electrophysiology, robotics, laser, and radiofrequency [52] - The company's plastic magnetic product obtained FDA certification in March 2023 and domestic medical registration in November 2023, becoming the only domestically produced magnetic stimulation device for body contouring [21] - The company's first-generation rehabilitation robot products have completed the certification process, forming a product matrix covering upper and lower limb rehabilitation [25] Market Potential - The aging population in China is increasing, leading to a growing demand for rehabilitation services, especially in elderly rehabilitation [12] - The rehabilitation market is expected to accelerate due to changes in population structure and increased health awareness [11] - The company is well-positioned to benefit from the expanding rehabilitation market, particularly in the fields of pelvic floor, mental, and neurological rehabilitation [4]

Company Overview - VISHEE Medical was established in 2001 and is headquartered in Nanjing, focusing on innovative medical devices. It is recognized as a national high-tech enterprise and listed on the Sci-Tech Innovation Board [3]. - The company specializes in rehabilitation medicine, offering high-quality products and solutions in areas such as pelvic floor rehabilitation, mental health recovery, neurological rehabilitation, and pediatric rehabilitation [3]. Financial Performance - In 2023, the company achieved total revenue of CNY 462.22 million, a year-on-year increase of 43.72%. The net profit attributable to shareholders was CNY 136.26 million, up 45.22% [3]. - The net profit after deducting non-recurring gains and losses was CNY 121.73 million, reflecting a significant increase of 58.93% [3]. - The company plans to distribute a high cash dividend, proposing a distribution of CNY 1.02 billion, with a plan to convert capital reserves into shares at a ratio of 4 shares for every 10 shares held [4]. Stock Incentive Plan - The performance assessment targets for the stock incentive plan remain unchanged, with the company aiming for an 80% revenue growth or a 110% net profit growth compared to 2022 [4]. - In Q1 2024, the stock incentive plan incurred a post-tax expense of CNY 599.96 million, with an expected increase in total stock payment for the year compared to 2023 [4]. Market Strategy and Product Development - The company is actively expanding into overseas markets, having received FDA certification for several products and participating in international exhibitions [4]. - The focus on medical aesthetics includes developing compliant products that replace imports, targeting women's health and aesthetic needs [5]. - The company has established six major technology platforms, including magnetic stimulation and robotic rehabilitation, to support its product offerings [6]. Future Outlook - The company anticipates a gradual increase in demand for medical equipment due to new policies, with expected performance growth in Q2 and Q3 of 2024 [7]. - The pelvic floor rehabilitation market is projected to maintain stable growth, with the company expanding its offerings to include comprehensive solutions for women's health throughout their life cycle [5].

关于以集中竞价交易方式回购公司股份累计达到 总股本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688580 证券简称：伟思医疗 公告编号：2024-019 南京伟思医疗科技股份有限公司 公司 2021 年年度权益分派现已实施完毕，公司本次以集中竞价交易方式回购 股份价格上限由不超过人民币 100 元/股（含）调整为不超过人民币 98.70 元/股 （含）。具体内容详见公司于 2022 年 6 月 16 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于 2021 年年度权益分派实施后调整回购股份价格 上限的公告》（公告编号：2022-041）。 （二）2023 年 11 月 9 日，公司召开第三届董事会第十六次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司通过集中竞价交易方 式回购公司已发行的人民币普通股（A 股），回购股份的资金总额不低于人民币 2,000 万元（含），不超过人民币 4,000 万元（含），回购股份的价格不超过人民币 90 元 ...

长江证券承销保荐有限公司 关于南京伟思医疗科技股份有限公司 使用部分超募资金永久补充流动资金并注销募集资金专户 的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）作为南 京伟思医疗科技股份有限公司（以下简称"伟思医疗"或"公司"）首次公开发行 股票并科创板上市项目的保荐机构，根据《上海证券交易所科创板上市公司自 律监管指引第1号——规范运作》《上市公司监管指引第2号——上市公司募集 资金管理和使用的监管要求》以及《上海证券交易所科创板股票上市规则》等 相关规定，就伟思医疗使用部分超募资金永久补充流动资金的事项进行了审慎 核查，核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意南京伟思医疗科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1213号）文核准，公司获准向 社会公众公开发行人民币普通股（A股）1,708.6667万股，每股发行价格为67.58 元，募集资金总额为人民币1,154,716,955.86元，扣除总发行费用人民币 91,729,995.18 元（不含税）后，募集资金净额为人民币1,062,986,960.68元。上 述募集资 ...